DOCSLIB.ORG

Supplementary Table 5. Pooled Analysis of Global Gene Expression

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Supplementary Table 5. Pooled analysis of global gene expression: Downregulated genes Criteria: 1) Signal-to-Noise ratio < -1.4 2) Fold Change < 0.5 (2 fold decrease after IPI-504 treatment) Down-regulated genes (101) NAME DESCRIPTION FC (Rx/NoRx) S2N P-value 1 ABCB8 ABCB8:ATP-binding cassette, sub-family B (MDR/TAP), member 8 0.09 -1.48 0.023 2 ACD ACD:adrenocortical dysplasia homolog (mouse) 0.40 -1.46 0.006 3 ACTB ACTB:actin, beta 0.31 -1.66 0.016 4 ADAM2 ADAM2:ADAM metallopeptidase domain 2 (fertilin beta) 0.35 -1.50 0.017 5 ADAMTS13 ADAMTS13:ADAM metallopeptidase with thrombospondin type 1 motif, 13 0.45 -1.41 0.018 6 ANKRD52 ANKRD52:ankyrin repeat domain 52 0.35 -1.52 0.009 7 AP4B1 AP4B1:adaptor-related protein complex 4, beta 1 subunit 0.46 -1.65 0.009 8 APLN APLN:apelin, AGTRL1 ligand 0.26 -1.74 0.016 9 ARHGEF10L ARHGEF10L:Rho guanine nucleotide exchange factor (GEF) 10-like 0.49 -1.49 0.012 10 ATP13A5 ATP13A5:ATPase type 13A5 0.30 -1.52 0.023 11 AURKB AURKB:aurora kinase B 0.35 -1.53 0.015 12 BCAR1 BCAR1:breast cancer anti-estrogen resistance 1 0.48 -1.80 0.011 13 BLOC1S1 BLOC1S1:biogenesis of lysosome-related organelles complex-1, subunit 1 0.34 -1.41 0.023 14 BTBD14B BTBD14B:BTB (POZ) domain containing 14B 0.41 -1.75 0.010 15 CAMK2A CAMK2A:calcium/calmodulin-dependent protein kinase (CaM kinase) II alpha 0.43 -1.53 0.019 16 CCDC70 CCDC70:coiled-coil domain containing 70 0.13 -1.80 0.006 17 CDC14C CDC14C:CDC14 cell division cycle 14 homolog C (S. cerevisiae) 0.04 -1.43 0.030 18 CDC20 CDC20:CDC20 cell division cycle 20 homolog (S. cerevisiae) 0.23 -1.43 0.013 19 CENPB CENPB:centromere protein B, 80kDa 0.47 -1.41 0.024 20 CFL1 CFL1:cofilin 1 (non-muscle) 0.33 -1.54 0.016 21 CHAF1A CHAF1A:chromatin assembly factor 1, subunit A (p150) 0.40 -1.42 0.002 22 CHCHD5 CHCHD5:coiled-coil-helix-coiled-coil-helix domain containing 5 0.33 -1.42 0.020 23 CHEK2 CHEK2:CHK2 checkpoint homolog (S. pombe) 0.41 -1.45 0.015 24 COPZ2 COPZ2:coatomer protein complex, subunit zeta 2 0.50 -1.93 0.009 25 CPSF3L CPSF3L:cleavage and polyadenylation specific factor 3-like 0.46 -1.44 0.012 26 CPZ CPZ:carboxypeptidase Z 0.29 -1.67 0.004 27 CRYGD CRYGD:crystallin, gamma D 0.39 -1.50 0.009 28 CST8 CST8:cystatin 8 (cystatin-related epididymal specific) 0.31 -1.40 0.024 29 DGCR8 DGCR8:DiGeorge syndrome critical region gene 8 0.37 -1.43 0.029 30 DNAHL1 DNAHL1:dynein, axonemal, heavy chain like 1 0.21 -2.55 0.002 31 DOT1L DOT1L:DOT1-like, histone H3 methyltransferase (S. cerevisiae) 0.37 -1.91 0.009 32 EDF1 EDF1:endothelial differentiation-related factor 1 0.42 -1.43 0.012 33 ENTPD6 ENTPD6:ectonucleoside triphosphate diphosphohydrolase 6 0.46 -1.45 0.001 34 EVI2B EVI2B:ecotropic viral integration site 2B 0.39 -1.42 0.013 35 FAM100B FAM100B:family with sequence similarity 100, member B 0.35 -1.58 0.008 36 FAM47A FAM47A:family with sequence similarity 47, member A 0.27 -1.46 0.029 37 FCHSD1 FCHSD1:FCH and double SH3 domains 1 0.20 -1.42 0.010 38 GJB3 GJB3:gap junction protein, beta 3, 31kDa (connexin 31) 0.41 -1.42 0.009 39 GLI4 GLI4:GLI-Kruppel family member GLI4 0.27 -1.57 0.022 40 GNAS GNAS:GNAS complex locus 0.33 -1.50 0.025 41 GPR144 GPR144:G protein-coupled receptor 144 0.31 -1.78 0.003 42 HRAS HRAS:v-Ha-ras Harvey rat sarcoma viral oncogene homolog 0.37 -1.46 0.014 43 HRK HRK:harakiri, BCL2 interacting protein (contains only BH3 domain) 0.38 -1.48 0.021 44 HSPB7 HSPB7:heat shock 27kDa protein family, member 7 (cardiovascular) 0.36 -1.60 0.003 45 IRF3 IRF3:interferon regulatory factor 3 0.45 -1.49 0.001 46 KCNG2 KCNG2:potassium voltage-gated channel, subfamily G, member 2 0.37 -1.43 0.010 47 KCNN1 KCNN1:potassium intermediate/small conductance calcium-activated channel 0.20 -4.43 0.000 48 KRT33A KRT33A:keratin 33A 0.38 -1.84 0.003 49 LAMP1 LAMP1:lysosomal-associated membrane protein 1 0.47 -1.46 0.021 50 LYL1 LYL1:lymphoblastic leukemia derived sequence 1 0.34 -1.49 0.025 51 MAP3K11 MAP3K11:mitogen-activated protein kinase kinase kinase 11 0.48 -1.74 0.004 52 MAPKAP1 MAPKAP1:mitogen-activated protein kinase associated protein 1 0.49 -1.54 0.010 53 MAZ MAZ:MYC-associated zinc finger protein (purine-binding transcription factor) 0.38 -1.41 0.013 54 MCM5 MCM5:MCM5 minichromosome maintenance deficient 5, cell division cycle 46 0.33 -1.55 0.016 55 MED25 MED25:mediator of RNA polymerase II transcription, subunit 25 homolog 0.29 -1.48 0.015 56 MRPS15 MRPS15:mitochondrial ribosomal protein S15 0.26 -1.43 0.017 57 MVP MVP:major vault protein 0.26 -1.48 0.024 58 MXD3 MXD3:MAX dimerization protein 3 0.39 -1.65 0.015 59 MYOHD1 MYOHD1:myosin head domain containing 1 0.39 -1.50 0.012 60 NFIX NFIX:nuclear factor I/X (CCAAT-binding transcription factor) 0.33 -1.47 0.012 61 NTN1 NTN1:netrin 1 0.42 -1.82 0.004 62 NUP210L NUP210L:nucleoporin 210kDa-like 0.27 -1.47 0.025 63 PARK7 PARK7:Parkinson disease (autosomal recessive, early onset) 7 0.41 -1.52 0.015 64 PHKG2 PHKG2:phosphorylase kinase, gamma 2 (testis) 0.17 -1.60 0.016 65 PORCN PORCN:porcupine homolog (Drosophila) 0.37 -1.52 0.025 66 PPIL2 PPIL2:peptidylprolyl isomerase (cyclophilin)-like 2 0.43 -1.44 0.027 67 PPP1R13L PPP1R13L:protein phosphatase 1, regulatory (inhibitor) subunit 13 like 0.41 -1.55 0.007 68 PPP1R2P9 PPP1R2P9:protein phosphatase 1, regulatory (inhibitor) subunit 2 pseudogene 9 0.22 -1.67 0.011 69 PPP2R5B PPP2R5B:protein phosphatase 2, regulatory subunit B (B56), beta isoform 0.41 -1.54 0.005 70 PSRC1 PSRC1:proline/serine-rich coiled-coil 1 0.36 -1.48 0.021 71 RALY RALY:RNA binding protein, autoantigenic 0.37 -1.49 0.017 72 RFNG RFNG:radical fringe homolog (Drosophila) 0.49 -1.56 0.008 73 S100A16 S100A16:S100 calcium binding protein A16 0.32 -2.06 0.006 74 SART1 SART1:squamous cell carcinoma antigen recognised by T cells 0.44 -1.42 0.024 75 SCYL1 SCYL1:SCY1-like 1 (S. cerevisiae) 0.31 -1.68 0.010 76 SIGIRR SIGIRR:single immunoglobulin and toll-interleukin 1 receptor (TIR) domain 0.31 -1.50 0.016 77 SILV SILV:silver homolog (mouse) 0.18 -1.64 0.009 78 SLC25A33 SLC25A33:solute carrier family 25, member 33 0.40 -1.45 0.006 79 SLC6A15 SLC6A15:solute carrier family 6, member 15 0.48 -2.16 0.006 80 SMAD9 SMAD9:SMAD, mothers against DPP homolog 9 (Drosophila) 0.40 -1.41 0.004 81 SPTAN1 SPTAN1:spectrin, alpha, non-erythrocytic 1 (alpha-fodrin) 0.36 -1.61 0.019 82 ST14 ST14:suppression of tumorigenicity 14 (colon carcinoma) 0.33 -1.43 0.009 83 STK24 STK24:serine/threonine kinase 24 (STE20 homolog, yeast) 0.46 -1.41 0.008 84 TACC3 TACC3:transforming, acidic coiled-coil containing protein 3 0.26 -1.78 0.009 85 TAF10 TAF10:TAF10 RNA polymerase II, TATA box binding protein-associated factor 0.23 -1.52 0.018 86 TBCD TBCD:tubulin-specific chaperone d 0.28 -1.45 0.016 87 TMSB10 TMSB10:thymosin, beta 10 0.32 -1.56 0.020 88 TNFAIP8L1 TNFAIP8L1:tumor necrosis factor, alpha-induced protein 8-like 1 0.46 -1.69 0.002 89 TNIP2 TNIP2:TNFAIP3 interacting protein 2 0.43 -1.68 0.005 90 TRAF4 TRAF4:TNF receptor-associated factor 4 0.40 -1.41 0.006 91 TREML2 TREML2:triggering receptor expressed on myeloid cells-like 2 0.07 -1.55 0.024 92 TRIM11 TRIM11:tripartite motif-containing 11 0.46 -1.54 0.008 93 TRIM40 TRIM40:tripartite motif-containing 40 0.15 -1.44 0.032 94 TROAP TROAP:trophinin associated protein (tastin) 0.35 -1.42 0.029 95 TSSK1 TSSK1:testis-specific serine kinase 1 0.34 -1.40 0.029 96 TYK2 TYK2:tyrosine kinase 2 0.45 -1.60 0.000 97 VIPR2 VIPR2:vasoactive intestinal peptide receptor 2 0.25 -1.73 0.013 98 ZDHHC12 ZDHHC12:zinc finger, DHHC-type containing 12 0.34 -1.40 0.007 99 ZDHHC14 ZDHHC14:zinc finger, DHHC-type containing 14 0.30 -1.55 0.009 100 ZNF101 ZNF101:zinc finger protein 101 0.38 -1.44 0.007 101 ZNF513 ZNF513:zinc finger protein 513 0.27 -1.53 0.023.
Recommended publications
  • Table S1 the Four Gene Sets Derived from Gene Expression Profiles of Escs and Differentiated Cells

    Table S1 the Four Gene Sets Derived from Gene Expression Profiles of Escs and Differentiated Cells

    Table S1 The four gene sets derived from gene expression profiles of ESCs and differentiated cells Uniform High Uniform Low ES Up ES Down EntrezID GeneSymbol EntrezID GeneSymbol EntrezID GeneSymbol EntrezID GeneSymbol 269261 Rpl12 11354 Abpa 68239 Krt42 15132 Hbb-bh1 67891 Rpl4 11537 Cfd 26380 Esrrb 15126 Hba-x 55949 Eef1b2 11698 Ambn 73703 Dppa2 15111 Hand2 18148 Npm1 11730 Ang3 67374 Jam2 65255 Asb4 67427 Rps20 11731 Ang2 22702 Zfp42 17292 Mesp1 15481 Hspa8 11807 Apoa2 58865 Tdh 19737 Rgs5 100041686 LOC100041686 11814 Apoc3 26388 Ifi202b 225518 Prdm6 11983 Atpif1 11945 Atp4b 11614 Nr0b1 20378 Frzb 19241 Tmsb4x 12007 Azgp1 76815 Calcoco2 12767 Cxcr4 20116 Rps8 12044 Bcl2a1a 219132 D14Ertd668e 103889 Hoxb2 20103 Rps5 12047 Bcl2a1d 381411 Gm1967 17701 Msx1 14694 Gnb2l1 12049 Bcl2l10 20899 Stra8 23796 Aplnr 19941 Rpl26 12096 Bglap1 78625 1700061G19Rik 12627 Cfc1 12070 Ngfrap1 12097 Bglap2 21816 Tgm1 12622 Cer1 19989 Rpl7 12267 C3ar1 67405 Nts 21385 Tbx2 19896 Rpl10a 12279 C9 435337 EG435337 56720 Tdo2 20044 Rps14 12391 Cav3 545913 Zscan4d 16869 Lhx1 19175 Psmb6 12409 Cbr2 244448 Triml1 22253 Unc5c 22627 Ywhae 12477 Ctla4 69134 2200001I15Rik 14174 Fgf3 19951 Rpl32 12523 Cd84 66065 Hsd17b14 16542 Kdr 66152 1110020P15Rik 12524 Cd86 81879 Tcfcp2l1 15122 Hba-a1 66489 Rpl35 12640 Cga 17907 Mylpf 15414 Hoxb6 15519 Hsp90aa1 12642 Ch25h 26424 Nr5a2 210530 Leprel1 66483 Rpl36al 12655 Chi3l3 83560 Tex14 12338 Capn6 27370 Rps26 12796 Camp 17450 Morc1 20671 Sox17 66576 Uqcrh 12869 Cox8b 79455 Pdcl2 20613 Snai1 22154 Tubb5 12959 Cryba4 231821 Centa1 17897
  • Suppl 1.1 All Data Dimethyl Labled

    Suppl 1.1 All Data Dimethyl Labled

    Fasta headers Protein names Gene names Uniprot Ratio H/L normalized exp01 Ratio H/L normalized exp02 Ratio H/L normalized exp03 Ratio H/L normalized exp04 Ratio H/L normalized exp05 Ratio H/L normalized exp06 Ratio H/L normalized exp07 Ratio H/L normalized exp08 Ratio H/L normalized exp09 Ratio H/L normalized exp10 Ratio H/L normalized exp11b Ratio H/L normalized exp12b Peptides exp01 Peptides exp02 Peptides exp03 Peptides exp04 Peptides exp05 Peptides exp06 Peptides exp07 Peptides exp08 Peptides exp09 Peptides exp10 Peptides exp11b Peptides exp12b Unique peptides exp01 Unique peptides exp02 Unique peptides exp03 Unique peptides exp04 Unique peptides exp05 Unique peptides exp06 Unique peptides exp07 Unique peptides exp08 >sp|P01876|IGHA1_HUMAN Ig alpha-1 chain C region OS=Homo sapiens GN=IGHA1 PE=1 SV=2Ig alpha-1 chain C region IGHA1 P01876 1,90 0,62 2,03 12,53 11,35 0,80 1,87 0,60 0,88 1,60 1,33 1,34 7 6 11 8 10 6 8 8 4 3 7 7 3 3 5 4 5 3 4 3 >sp|P02647|APOA1_HUMAN Apolipoprotein A-I OS=Homo sapiens GN=APOA1 PE=1 SV=1;>tr|F8W696|F8W696_HUMAN Truncated apolipoprotein A-I OS=Homo sapiens GN=APOA1 PE=1 SV=1Apolipoprotein A-I;Truncated apolipoprotein A-I APOA1 P02647 1,71 1,13 0,77 1,73 0,89 1,12 0,61 0,84 1,53 1,46 1,16 0,86 17 16 17 18 16 14 13 16 17 13 14 17 17 16 17 18 16 14 13 16 >sp|P01024|CO3_HUMAN Complement C3 OS=Homo sapiens GN=C3 PE=1 SV=2Complement C3;Complement C3 beta chain;Complement C3 alpha chain;C3a anaphylatoxin;Acylation stimulating protein;Complement C3b alpha chain;Complement C3c alpha chain fragment 1;Complement C3dg
  • To Study Mutant P53 Gain of Function, Various Tumor-Derived P53 Mutants

    To Study Mutant P53 Gain of Function, Various Tumor-Derived P53 Mutants

    Differential effects of mutant TAp63γ on transactivation of p53 and/or p63 responsive genes and their effects on global gene expression. A thesis submitted in partial fulfillment of the requirements for the degree of Master of Science By Shama K Khokhar M.Sc., Bilaspur University, 2004 B.Sc., Bhopal University, 2002 2007 1 COPYRIGHT SHAMA K KHOKHAR 2007 2 WRIGHT STATE UNIVERSITY SCHOOL OF GRADUATE STUDIES Date of Defense: 12-03-07 I HEREBY RECOMMEND THAT THE THESIS PREPARED UNDER MY SUPERVISION BY SHAMA KHAN KHOKHAR ENTITLED Differential effects of mutant TAp63γ on transactivation of p53 and/or p63 responsive genes and their effects on global gene expression BE ACCEPTED IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE OF Master of Science Madhavi P. Kadakia, Ph.D. Thesis Director Daniel Organisciak , Ph.D. Department Chair Committee on Final Examination Madhavi P. Kadakia, Ph.D. Steven J. Berberich, Ph.D. Michael Leffak, Ph.D. Joseph F. Thomas, Jr., Ph.D. Dean, School of Graduate Studies 3 Abstract Khokhar, Shama K. M.S., Department of Biochemistry and Molecular Biology, Wright State University, 2007 Differential effect of TAp63γ mutants on transactivation of p53 and/or p63 responsive genes and their effects on global gene expression. p63, a member of the p53 gene family, known to play a role in development, has more recently also been implicated in cancer progression. Mice lacking p63 exhibit severe developmental defects such as limb truncations, abnormal skin, and absence of hair follicles, teeth, and mammary glands. Germline missense mutations of p63 have been shown to be responsible for several human developmental syndromes including SHFM, EEC and ADULT syndromes and are associated with anomalies in the development of organs of epithelial origin.
  • ADAM10 Site-Dependent Biology: Keeping Control of a Pervasive Protease

    ADAM10 Site-Dependent Biology: Keeping Control of a Pervasive Protease

    International Journal of Molecular Sciences Review ADAM10 Site-Dependent Biology: Keeping Control of a Pervasive Protease Francesca Tosetti 1,* , Massimo Alessio 2, Alessandro Poggi 1,† and Maria Raffaella Zocchi 3,† 1 Molecular Oncology and Angiogenesis Unit, IRCCS Ospedale Policlinico S. Martino Largo R. Benzi 10, 16132 Genoa, Italy; [email protected] 2 Proteome Biochemistry, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy; [email protected] 3 Division of Immunology, Transplants and Infectious Diseases, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy; [email protected] * Correspondence: [email protected] † These authors contributed equally to this work as last author. Abstract: Enzymes, once considered static molecular machines acting in defined spatial patterns and sites of action, move to different intra- and extracellular locations, changing their function. This topological regulation revealed a close cross-talk between proteases and signaling events involving post-translational modifications, membrane tyrosine kinase receptors and G-protein coupled recep- tors, motor proteins shuttling cargos in intracellular vesicles, and small-molecule messengers. Here, we highlight recent advances in our knowledge of regulation and function of A Disintegrin And Metalloproteinase (ADAM) endopeptidases at specific subcellular sites, or in multimolecular com- plexes, with a special focus on ADAM10, and tumor necrosis factor-α convertase (TACE/ADAM17), since these two enzymes belong to the same family, share selected substrates and bioactivity. We will discuss some examples of ADAM10 activity modulated by changing partners and subcellular compartmentalization, with the underlying hypothesis that restraining protease activity by spatial Citation: Tosetti, F.; Alessio, M.; segregation is a complex and powerful regulatory tool.
  • Role and Regulation of the Metalloproteinase ADAM8 in Liver Inflammation and Hepatocellular Carcinoma

    Role and Regulation of the Metalloproteinase ADAM8 in Liver Inflammation and Hepatocellular Carcinoma

    Role and Regulation of the Metalloproteinase ADAM8 in Liver Inflammation and Hepatocellular Carcinoma Von der Fakultät für Mathematik, Informatik und Naturwissenschaften der RWTH Aachen University zur Erlangung des akademischen Grades einer Doktorin der Naturwissenschaften genehmigte Dissertation vorgelegt von Tanzeela Awan M. Phil Pharmacology aus Layyah, Pakistan Berichter: Herr Universitätsprofessor Dr. rer. nat. Andreas Ludwig Frau Universitätsprofessorin Dr. phil. nat. Gabriele Pradel Herr Universitätsprofessor Dr. rer. nat. Martin Zenke Tag der mündlichen Prüfung: 11.01.2021 Diese Dissertation ist auf den Internetseiten der Universitätsbibliothek online verfügbar. Table of Contents Table of Contents 1 Introduction .......................................................................................... 1 1.1 The Liver .............................................................................................. 1 1.1.1 Cells of the liver ................................................................................... 1 1.1.2 Liver inflammation ............................................................................... 3 1.1.3 Liver carcinoma .................................................................................... 6 1.1.4 Integrin and focal adhesion kinase signalling ...................................... 7 1.2 Metalloproteinases ................................................................................ 9 1.2.1 ADAM proteases: structure and functions of different domains ....... 10 1.3 ADAM8 .............................................................................................
  • Structural and Biochemical Changes Underlying a Keratoderma-Like Phenotype in Mice Lacking Suprabasal AP1 Transcription Factor Function

    Structural and Biochemical Changes Underlying a Keratoderma-Like Phenotype in Mice Lacking Suprabasal AP1 Transcription Factor Function

    Citation: Cell Death and Disease (2015) 6, e1647; doi:10.1038/cddis.2015.21 OPEN & 2015 Macmillan Publishers Limited All rights reserved 2041-4889/15 www.nature.com/cddis Structural and biochemical changes underlying a keratoderma-like phenotype in mice lacking suprabasal AP1 transcription factor function EA Rorke*,1, G Adhikary2, CA Young2, RH Rice3, PM Elias4, D Crumrine4, J Meyer4, M Blumenberg5 and RL Eckert2,6,7,8 Epidermal keratinocyte differentiation on the body surface is a carefully choreographed process that leads to assembly of a barrier that is essential for life. Perturbation of keratinocyte differentiation leads to disease. Activator protein 1 (AP1) transcription factors are key controllers of this process. We have shown that inhibiting AP1 transcription factor activity in the suprabasal murine epidermis, by expression of dominant-negative c-jun (TAM67), produces a phenotype type that resembles human keratoderma. However, little is understood regarding the structural and molecular changes that drive this phenotype. In the present study we show that TAM67-positive epidermis displays altered cornified envelope, filaggrin-type keratohyalin granule, keratin filament, desmosome formation and lamellar body secretion leading to reduced barrier integrity. To understand the molecular changes underlying this process, we performed proteomic and RNA array analysis. Proteomic study of the corneocyte cross-linked proteome reveals a reduction in incorporation of cutaneous keratins, filaggrin, filaggrin2, late cornified envelope precursor proteins, hair keratins and hair keratin-associated proteins. This is coupled with increased incorporation of desmosome linker, small proline-rich, S100, transglutaminase and inflammation-associated proteins. Incorporation of most cutaneous keratins (Krt1, Krt5 and Krt10) is reduced, but incorporation of hyperproliferation-associated epidermal keratins (Krt6a, Krt6b and Krt16) is increased.
  • Investigation of the Underlying Hub Genes and Molexular Pathogensis in Gastric Cancer by Integrated Bioinformatic Analyses

    Investigation of the Underlying Hub Genes and Molexular Pathogensis in Gastric Cancer by Integrated Bioinformatic Analyses

    bioRxiv preprint doi: https://doi.org/10.1101/2020.12.20.423656; this version posted December 22, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Investigation of the underlying hub genes and molexular pathogensis in gastric cancer by integrated bioinformatic analyses Basavaraj Vastrad1, Chanabasayya Vastrad*2 1. Department of Biochemistry, Basaveshwar College of Pharmacy, Gadag, Karnataka 582103, India. 2. Biostatistics and Bioinformatics, Chanabasava Nilaya, Bharthinagar, Dharwad 580001, Karanataka, India. * Chanabasayya Vastrad [email protected] Ph: +919480073398 Chanabasava Nilaya, Bharthinagar, Dharwad 580001 , Karanataka, India bioRxiv preprint doi: https://doi.org/10.1101/2020.12.20.423656; this version posted December 22, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Abstract The high mortality rate of gastric cancer (GC) is in part due to the absence of initial disclosure of its biomarkers. The recognition of important genes associated in GC is therefore recommended to advance clinical prognosis, diagnosis and and treatment outcomes. The current investigation used the microarray dataset GSE113255 RNA seq data from the Gene Expression Omnibus database to diagnose differentially expressed genes (DEGs). Pathway and gene ontology enrichment analyses were performed, and a proteinprotein interaction network, modules, target genes - miRNA regulatory network and target genes - TF regulatory network were constructed and analyzed. Finally, validation of hub genes was performed. The 1008 DEGs identified consisted of 505 up regulated genes and 503 down regulated genes.
  • Table S1. the Clinicopathological Data of the Laryngeal Cancer Cases Involved in the Primary Tissue Culture

    Table S1. the Clinicopathological Data of the Laryngeal Cancer Cases Involved in the Primary Tissue Culture

    Table S1. The clinicopathological data of the laryngeal cancer cases involved in the primary tissue culture Case Gender Age at Smoking Alcohol Histological type TNM Tumor coding* diagnosis status status staging† differentiation LC01 male 63 Yes Yes Supraglottic squamous cell carcinoma T4N2M0 Moderate LC14 male 73 Yes Yes Supraglottic squamous cell carcinoma T3N2M0 Moderate LC53 male 54 Yes No Supraglottic squamous cell carcinoma T3N2M0 Moderate LC95 male 50 Yes Yes Glottic squmamous cell carcinoma T3N1M0 Poor *LC represents laryngeal cancer. † staged according to Sixth Edition (2002) of the AJCC-UICC TNM Staging System. Table S2. The clinical characteristics of the 149 patients with laryngeal SCC used for ELISA Variable N (%) Variable N(%) Age (years) Disease stage ≤55 58 (38.9) I 33 (22.1) >55 91 (61.1) II 32 (21.5) Median (range) 58 (35-82) III 41 (27.5) IV 41 (27.5) Missing 2 (1.3) Gender T stage* Male 140 (94.0) T1 33 (21.5) Female 9 (6.0) T2 36 (24.2) T3 52 (34.9) T4 26 (17.4) Missing 2 (1.3) Smoking status Lymph node status Ever 124 (83.2) pN0 110 (73.8) Never 11 (7.4) pN+ 37 (24.8) Missing 14 (9.4) Missing 2 (1.3) Alcohol status Tumor differentiation Yes 84 (56.4) well 34 (22.8) No 51(34.2) moderate 78 (52.3) Missing 14 (9.4) poor 24 (16.1) Missing 13 (8.7) Anatomical region Glottis 82 (55.0) Supraglottis 60 (40.3) Subglottis 1 (0.7) Missing 6 (4.0) *staged according to Sixth Edition (2002) of the AJCC-UICC TNM Staging System.
  • Supp Material.Pdf

    Supp Material.Pdf

    Simon et al. Supplementary information: Table of contents p.1 Supplementary material and methods p.2-4 • PoIy(I)-poly(C) Treatment • Flow Cytometry and Immunohistochemistry • Western Blotting • Quantitative RT-PCR • Fluorescence In Situ Hybridization • RNA-Seq • Exome capture • Sequencing Supplementary Figures and Tables Suppl. items Description pages Figure 1 Inactivation of Ezh2 affects normal thymocyte development 5 Figure 2 Ezh2 mouse leukemias express cell surface T cell receptor 6 Figure 3 Expression of EZH2 and Hox genes in T-ALL 7 Figure 4 Additional mutation et deletion of chromatin modifiers in T-ALL 8 Figure 5 PRC2 expression and activity in human lymphoproliferative disease 9 Figure 6 PRC2 regulatory network (String analysis) 10 Table 1 Primers and probes for detection of PRC2 genes 11 Table 2 Patient and T-ALL characteristics 12 Table 3 Statistics of RNA and DNA sequencing 13 Table 4 Mutations found in human T-ALLs (see Fig. 3D and Suppl. Fig. 4) 14 Table 5 SNP populations in analyzed human T-ALL samples 15 Table 6 List of altered genes in T-ALL for DAVID analysis 20 Table 7 List of David functional clusters 31 Table 8 List of acquired SNP tested in normal non leukemic DNA 32 1 Simon et al. Supplementary Material and Methods PoIy(I)-poly(C) Treatment. pIpC (GE Healthcare Lifesciences) was dissolved in endotoxin-free D-PBS (Gibco) at a concentration of 2 mg/ml. Mice received four consecutive injections of 150 μg pIpC every other day. The day of the last pIpC injection was designated as day 0 of experiment.
  • Supplementary Table S4. FGA Co-Expressed Gene List in LUAD

    Supplementary Table S4. FGA Co-Expressed Gene List in LUAD

    Supplementary Table S4. FGA co-expressed gene list in LUAD tumors Symbol R Locus Description FGG 0.919 4q28 fibrinogen gamma chain FGL1 0.635 8p22 fibrinogen-like 1 SLC7A2 0.536 8p22 solute carrier family 7 (cationic amino acid transporter, y+ system), member 2 DUSP4 0.521 8p12-p11 dual specificity phosphatase 4 HAL 0.51 12q22-q24.1histidine ammonia-lyase PDE4D 0.499 5q12 phosphodiesterase 4D, cAMP-specific FURIN 0.497 15q26.1 furin (paired basic amino acid cleaving enzyme) CPS1 0.49 2q35 carbamoyl-phosphate synthase 1, mitochondrial TESC 0.478 12q24.22 tescalcin INHA 0.465 2q35 inhibin, alpha S100P 0.461 4p16 S100 calcium binding protein P VPS37A 0.447 8p22 vacuolar protein sorting 37 homolog A (S. cerevisiae) SLC16A14 0.447 2q36.3 solute carrier family 16, member 14 PPARGC1A 0.443 4p15.1 peroxisome proliferator-activated receptor gamma, coactivator 1 alpha SIK1 0.435 21q22.3 salt-inducible kinase 1 IRS2 0.434 13q34 insulin receptor substrate 2 RND1 0.433 12q12 Rho family GTPase 1 HGD 0.433 3q13.33 homogentisate 1,2-dioxygenase PTP4A1 0.432 6q12 protein tyrosine phosphatase type IVA, member 1 C8orf4 0.428 8p11.2 chromosome 8 open reading frame 4 DDC 0.427 7p12.2 dopa decarboxylase (aromatic L-amino acid decarboxylase) TACC2 0.427 10q26 transforming, acidic coiled-coil containing protein 2 MUC13 0.422 3q21.2 mucin 13, cell surface associated C5 0.412 9q33-q34 complement component 5 NR4A2 0.412 2q22-q23 nuclear receptor subfamily 4, group A, member 2 EYS 0.411 6q12 eyes shut homolog (Drosophila) GPX2 0.406 14q24.1 glutathione peroxidase
  • KT33A Antibody Cat

    KT33A Antibody Cat

    KT33A Antibody Cat. No.: 55-790 KT33A Antibody Specifications HOST SPECIES: Rabbit SPECIES REACTIVITY: Mouse HOMOLOGY: Predicted species reactivity based on immunogen sequence: Human This KT33A antibody is generated from rabbits immunized with a KLH conjugated IMMUNOGEN: synthetic peptide between 56-85 amino acids from the N-terminal region of human KT33A. TESTED APPLICATIONS: WB APPLICATIONS: For WB starting dilution is: 1:1000 PREDICTED MOLECULAR 46 kDa WEIGHT: Properties This antibody is purified through a protein A column, followed by peptide affinity PURIFICATION: purification. CLONALITY: Polyclonal ISOTYPE: Rabbit Ig October 1, 2021 1 https://www.prosci-inc.com/kt33a-antibody-55-790.html CONJUGATE: Unconjugated PHYSICAL STATE: Liquid BUFFER: Supplied in PBS with 0.09% (W/V) sodium azide. CONCENTRATION: batch dependent Store at 4˚C for three months and -20˚C, stable for up to one year. As with all antibodies STORAGE CONDITIONS: care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures. Additional Info OFFICIAL SYMBOL: KRT33A Keratin, type I cuticular Ha3-I, Hair keratin, type I Ha3-I, Keratin-33A, K33A, KRT33A, HHA3- ALTERNATE NAMES: I, HKA3A, KRTHA3A ACCESSION NO.: O76009 GENE ID: 3883 USER NOTE: Optimal dilutions for each application to be determined by the researcher. Background and References The protein encoded by this gene is a member of the keratin gene family. It is one of the type I hair keratin genes which are clustered in a region of chromosome 17q12-q21 and have the same direction of transcription. As a type I hair keratin, it is an acidic protein BACKGROUND: which heterodimerizes with type II keratins to form hair and nails.
  • The Correlation of Keratin Expression with In-Vitro Epithelial Cell Line Differentiation

    The Correlation of Keratin Expression with In-Vitro Epithelial Cell Line Differentiation

    The correlation of keratin expression with in-vitro epithelial cell line differentiation Deeqo Aden Thesis submitted to the University of London for Degree of Master of Philosophy (MPhil) Supervisors: Professor Ian. C. Mackenzie Professor Farida Fortune Centre for Clinical and Diagnostic Oral Science Barts and The London School of Medicine and Dentistry Queen Mary, University of London 2009 Contents Content pages ……………………………………………………………………......2 Abstract………………………………………………………………………….........6 Acknowledgements and Declaration……………………………………………...…7 List of Figures…………………………………………………………………………8 List of Tables………………………………………………………………………...12 Abbreviations….………………………………………………………………..…...14 Chapter 1: Literature review 16 1.1 Structure and function of the Oral Mucosa……………..…………….…..............17 1.2 Maintenance of the oral cavity...……………………………………….................20 1.2.1 Environmental Factors which damage the Oral Mucosa………. ….…………..21 1.3 Structure and function of the Oral Mucosa ………………...….……….………...21 1.3.1 Skin Barrier Formation………………………………………………….……...22 1.4 Comparison of Oral Mucosa and Skin…………………………………….……...24 1.5 Developmental and Experimental Models used in Oral mucosa and Skin...……..28 1.6 Keratinocytes…………………………………………………….….....................29 1.6.1 Desmosomes…………………………………………….…...............................29 1.6.2 Hemidesmosomes……………………………………….…...............................30 1.6.3 Tight Junctions………………………….……………….…...............................32 1.6.4 Gap Junctions………………………….……………….….................................32